Oğuz AYDIN, Sercan ERGÜN, Sezgin GÜNEŞ, Recep BÜYÜKALPELLİ

Glutamate transporter SLC1A1 is associated with clear cell renal cell carcinoma

Background/aim: This study aimed to comparatively analyze the expression levels of the SLC1A1 gene in renal specimens from tumorsand adjacent healthy kidney tissues of patients with clear cell renal cell carcinoma (ccRCC).Material and methods: Nineteen patients diagnosed with ccRCC were included in the study. The expression levels of the SLC1A1 andGAPDH genes were measured in tumor and formalin-fixed paraffin-embedded (FFPE) tissue specimens from the adjacent healthykidney of each subject. Via the GEPIA database, the distribution of SLC1A1 gene expressions in ccRCC and healthy kidney tissues wasobtained. The relative expression of SLC1A1 was evaluated for the association with the clinical parameters of the patients.Results: The expression of the SLC1A1 gene was significantly higher in males than females (P = 0.029). Also, there were statisticallysignificant associations between stages II–IV and Fuhrman grades 2–4 with respect to SLC1A1 gene expression (P < 0.001 for both).Moreover, low levels of red blood cell and hemoglobin counts were significantly associated with the SLC1A1 expression (P < 0.001 andP = 0.005, respectively). The expression of the SLC1A1 gene in tumor tissues increased approximately 3 times compared with normalkidney tissues (P < 0.05). According to the GEPIA database, SLC1A1 gene expression is significantly higher in ccRCC patients thanhealthy persons (P = 0.01).Conclusion: The change in the expression of SLC1A1 may be crucial for ccRCC pathophysiology.

PDF

___

1. Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol-Renal 2017; 313: F145-F154.
2. Parker WP, Cheville JC, Frank I, Zaid HB, Lohse CM, Boorjian SA, Leibovich BC, Thompson RH. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol 2017; 71: 665-673.
3. Soultati A, Stares M, Swanton C, Larkin J, Turajlic S. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? Curr Opin Urol 2015; 25: 358-366.
4. Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 2015; 48: 166-174.
5. Xing T, He H. Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chinese J Cancer Res 2016; 28: 80.
6. Beaudin S, Welsh J. 1,25-Dihydroxyvitamin D induces the glutamate transporter SLC1A1 and alters glutamate handling in non-transformed mammary cells. Mol Cell Endocrinol 2016; 424: 34-41.
7. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45: W98-W102.
8. Kluzek K, Bluyssen H A, Wesoly J. The epigenetic landscape of clear-cell renal cell carcinoma. J Kidney Cancer VHL 2015; 2: 90.
9. Mozayen M, Tesfaye A, Katato K. Prognostic significance of degree of anemia in renal cell carcinoma. J Clin Oncol 2012; 30 (Suppl. 5): 469.
10. Talmon GA. Pure erythropoiesis in clear cell renal cell carcinoma. Int J Surg Pathol 2010; 18: 544-546.
11. Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL. Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 2014; 5: 8853.
12. Bianchi MG, Gazzola GC, Tognazzi L, Bussolati O. C6 glioma cells differentiated by retinoic acid overexpress the glutamate transporter excitatory amino acid carrier 1 (EAAC1). Neuroscience 2008; 151: 1042-1052.
13. Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, et al. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neuroscience 2006; 9: 119-126.
14. Ganesamoni R, Bhattacharyya S, Kumar S, Chauhan A, Mete UK, Agarwal MM, Mavuduru R, Kaushik G, Mandal AK, Singh SK. Status of oxidative stress in patients with renal cell carcinoma. J Urol 2012; 187: 1172-1176.